- Two-Year Contract from the Defense Threat Reduction Agency Will Fund the Advanced Development of Cethromycin as a Potential Broad-Spectrum Medical
CHICAGO, Aug. 13 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced that the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense has awarded the Company a two-year contract worth up to $3.8 million to further study cethromycin as a potential broad-spectrum medical countermeasure. The contract, part of the agency's Transformational Medical Technologies Initiative (TMTI), will fund NDA-enabling studies evaluating cethromycin's efficacy in combating Category A and B bioterror agents such as Fransicella tularensis (tularemia), Yersinia pestis (plague) and Burkholderia pseudomallei (melioidosis).
"We are very excited to partner with DTRA and share its mission to reduce the threat of biological warfare and bioterrorism," stated Dr. Michael T. Flavin, chairman and chief executive officer of Advanced Life Sciences. "We believe this government contract further validates the potential of cethromycin as a biodefense agent, and it enables us to conduct pivotal studies to expand cethromycin's potential spectrum of activity beyond the success that was demonstrated in preventing inhalation anthrax."
Dr. Herbert Schweizer, Professor and Associate Program Director, Rocky
Mountain Regional Center of Excellence for Biodefense and Emerging
Infectious Diseases Research, Colorado State University stated, "Our
initial evaluation of cethr
|SOURCE Advanced Life Sciences Holdings, Inc.|
Copyright©2008 PR Newswire.
All rights reserved